1 **Early prediction of preeclampsia in pregnancy with circulating, cell-free RNA**
2

3 Mira N. Moufarrej[1], Ronald J. Wong[2], Ana A. Campos[2], Cecele C. Quaintance[2], Rene V. Sit[3],
4 Michelle Tan[3], Norma F. Neff[3], Maurice L. Druzin[4], Virginia D. Winn[4], Gary M. Shaw[2], David
5 K. Stevenson[2], Stephen R. Quake[1,3,5,*]
6

[1] Department of Bioengineering, Stanford University, Stanford, CA USA 94305
[2] Department of Pediatrics, Stanford University School of Medicine, Stanford, CA USA 94305
[3] Chan Zuckerberg Biohub, Stanford, CA USA 94305
[4] Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford,
CA USA 94305
[5] Department of Applied Physics, Stanford University, Stanford, CA USA 94305
13

[*] Corresponding author: steve@quake-lab.org

Abstract

Liquid biopsies that measure circulating, cell-free RNA (cfRNA) offer an unprecedented
opportunity to noninvasively study the development of pregnancy-related complications and to
bridge gaps in clinical care. Here, we identify cfRNA transcriptomic changes across gestation and
at post-partum that are associated with preeclampsia (PE), a multi-organ syndrome diagnosed after
20 weeks of gestation, using 118 samples from 42 pregnant mothers (18 normotensive (NT), 24
with PE). We find that changes in cfRNA gene expression between NT and PE mothers are most
striking and stable early in gestation, suggesting that the identified cfRNA signals may correlate
with PE pathogenesis. These changes also reflect our understanding of the known biology of PE,
as supported by gene ontology analysis. Finally, we identify and independently validate (8 NT, 8
with PE/gestational hypertension) 11 genes, which when measured between 5–16 weeks of
gestation can form a liquid biopsy test with clinically relevant specificity (88% [55–99%]) and
sensitivity (100% [74–100%]) (All reported as value, [95% confidence interval]). Taken together,
these results show that cfRNA measurements can form the basis of a test that would predict PE
early in pregnancy, which has been an important and until now unrealized objective for obstetric
care, and can help characterize the pathogenesis of PE in real time.

Introduction
Advances in obstetrics and neonatology have significantly mitigated many of the adverse
pregnancy outcomes related to preterm birth (PTB) and preeclampsia (PE) [1,2]. Nonetheless, the
standards of care implemented today focus on how to treat a mother and child once a complication
has been diagnosed, proving both insufficient and costly [3–6]: PE and related hypertensive disorders
cause 14% of maternal deaths each year globally, second only to hemorrhage [7], and cost $2B in
care in the first year following delivery [5]. Worse, 3 out of 5 maternal deaths in the US are
preventable and often associated with a missed or delayed complication diagnosis [8]. Such
outcomes highlight the need for novel tools that would aid in identifying which women are at risk
for hypertensive diseases, such as PE, before clinical presentation. Indeed, early prediction of PE,
which has not been achieved to date, may enable prevention or reduction of a pregnant mother's
risk of developing PE [9,10] if coupled with appropriate treatment.
45

PE is a leading pregnancy-related complication that globally affects 4–5% of pregnancies [11–13] and
is associated with a significant increase in adverse maternal (e.g., maternal death, heart attack,
stroke, seizures, and hemorrhage) and perinatal (e.g., fetal growth restriction and PTB coupled
with respiratory distress syndrome, intraventricular hemorrhage, cerebral palsy, and
bronchopulmonary dysplasia) outcomes [14–18]. Long-term, PE presents an increased maternal risk
for cardiovascular [19,20] and kidney [21,22] diseases. Formally defined as new-onset hypertension with
proteinuria or other end-organ damage (e.g., liver, brain) occurring after 20 weeks of gestation [23],
PE can clinically manifest anytime thereafter, including into the post-partum period [24]. Detection
and diagnosis itself however can prove challenging as early signs like headaches and nausea can
be easily confused with general pregnancy discomfort and because PE shares many signs and
symptoms with other common complications like gestational thrombocytopenia and chronic
hypertension.
58
To date, no recommended test exists that can predict the future onset of PE early in pregnancy [9],
and investigational approaches that measure diverse biophysical and biochemical signals including
the measurement of two angiogenic factors (soluble fms-like tyrosine kinase-1 (sFlt1), placental
growth factor (PlGF)) in the second and third trimesters [25,26] have at best only moderate positive
predictive values (8–33%) [27]. A test with good performance metrics could guide the prophylactic
use of low-dose aspirin, which has been shown to reduce the risk of PE if initially administered
before 16 weeks of gestation [10,28]. Liquid biopsies that measure plasma cell-free RNA (cfRNA)
suggest a means to bridge this gap in clinical care; however, until recently, such work often failed
to progress beyond initial discovery [29]. Recent efforts have instead either focused on confirmation
of PE at clinical diagnosis [30] or on limited discovery (n = 8 with PE/gestational hypertension)
earlier in pregnancy with encouraging but unvalidated results [31]. Consequently, the prediction of
PE early in gestation (≤ 16 weeks), long before symptoms present when, such a test would be most
useful to guide the prophylactic use of potential therapeutics (e.g., low-dose aspirin) remains a key
objective to improve obstetric care [9].
73
Clinical care may also be improved by a better understanding of the pathogenesis of PE. PE is a
disease specific to humans as it does not occur in other species [32], and elucidating its pathogenesis
has proven especially challenging. Broadly, it is accepted that PE occurs in two stages – abnormal
placentation occurring early in pregnancy followed by systemic endothelial dysfunction [15,32,33].
Because PE can clinically present any time after 20 weeks of gestation and with a diversity of
symptoms, significant effort has been made to subclassify the disease based upon the timing of
onset (i.e., early-onset at < 34 weeks of gestation vs late-onset thereafter) as a proxy for pathology
[34,35]; however, debate over the significance of such subtypes is still ongoing [32,33,36,37]. Noninvasive
methods like liquid biopsies present a means to indirectly observe pathogenesis in real time and
identify biological changes associated with PE for all proposed subtypes both prior to and at
diagnosis.
85
Here, we report that cfRNA transcriptomic changes can distinguish between normotensive (NT)
and PE pregnancies before clinical diagnosis and across gestation: early (5–12 weeks), mid (13–
18 weeks), and late (23–33 weeks), and even into the post-partum period (0–2 weeks after delivery)
regardless of PE subtype. Interestingly, the majority of these cfRNA changes are most striking
early in pregnancy suggesting that the identified cfRNA signal may correlate with PE
pathogenesis, which is thought to also occur at this time. Indeed, gene ontology (GO) analysis

identified pathways that reflect known PE biology. Finally, we identified and independently
validated (n = 8 NT, 8 PE/gestational hypertension) 11 genes that when measured between 5–16
weeks of gestation can form a predictive PE signature with a specificity of 88% [55–99%] and
sensitivity of 100% [74–100%] (AUC=94%, [79–100%]) (All reported as value, [95% confidence
interval]). Taken together, our results showed that cfRNA measurements can form the basis for a
clinically relevant test that would predict PE well before clinical presentation and can help
characterize the pathogenesis of PE in real time.
99
100 **Results**
101
Clinical study design
To identify changes associated with PE well before traditional diagnoses, we designed a
prospective study and recruited pregnant mothers at their first clinical visit, between 5–12 weeks
of gestation, of which 66 were included in this study (28 NT, 38 with PE). For each participant,
we then collected 4 plasma samples corresponding to early (5–12 weeks), mid- (13–18 weeks),
and late (23–33 weeks) gestation, and post-partum (0–2 weeks after delivery) (Fig 1A). We also
recorded maternal pre-pregnancy and pregnancy characteristics (Table S1). We defined a
pregnancy as NT if it was both uncomplicated and went to full-term ($\geq$ 37 weeks) and as PE based
on current guidelines (see Methods). For mothers who developed PE, all antenatal blood samples
were collected prior to diagnosis. To verify our results, we then split this larger group into
discovery (n = 49, [20 NT, 29 with PE]) and validation (n = 17, [8 NT, 9 with PE]) cohorts that
were processed at separate times. Our final analysis included a subset of these samples that passed
pre-defined quality metrics as discussed in the Supplement (Supp. note 1, Methods, Fig S1,2).
115
116 After confirming sample quality, 147 samples from 57 mothers (26 NT, 31 with PE) were included
117 in the final analysis. Specifically, 118 samples from 42 participants (18 NT, 24 with PE) were
118 sequenced (RNAseq) in discovery and 29 samples from 15 participants (8 NT, 7 with PE) were
119 processed using reverse-transcription quantitative polymerase chain reaction (RT-qPCR) in
120 validation.
121
In the discovery cohort, we analyzed cfRNA from samples from four timepoints (early, mid-, and
late gestation, and post-partum); whereas in validation, we focused on samples collected at early
and mid-gestation because of the aforementioned clinical need for high quality predictive tests for
PE early in gestation (Fig 1A). Across gestational timepoints in both cohorts, we found no
significant difference in sampling time between PE and NT groups ($p \geq 0.7$, 0.06). Known risk
factors for PE, such as pre-pregnancy maternal body mass index (BMI), maternal age, and the
number of prior pregnancies, followed expected trends, but were not significantly different
between PE and NT groups ($p \geq 0.19$, 0.52) (Fig 1B).
130
In mothers who later developed PE, a small fraction, 4 (17%) and 1 (14%) had a history of PE in
the discovery and validation cohorts, respectively. We also observed no significant difference (p
= 0.14, 1.0) in gestational age at onset between those who experienced mild (n = 11, 4) as compared
with severe (n = 13, 3) symptoms (Fig 1C). Furthermore, 10 mothers who developed PE also
delivered preterm (n = 9, 1) as compared with no mothers in the NT group as reflected by
significantly different gestational ages at delivery ($p = 10^{-5}$, 0.25, one-sided test) (Fig 1D), which
was consistent both with our NT group inclusion criteria and with epidemiological evidence that

PE increases the risk of spontaneous or indicated preterm delivery [5,27] (values reported as
discovery, validation, Mann-Whitney rank test).
140
Identification of cfRNA changes PE across gestation in mothers who developed PE
To identify gene changes associated with PE across pregnancy, we performed differential
expression profiling using the discovery cohort and excluded post-partum samples, which instead
served as a hold-out set, since they presented a clear break in gestational time and a marked change
in physiology – specifically the absence of contributions from the fetus and placenta. This analysis
identified 556 differentially expressed genes (DEGs) that differed across gestation between
mothers who later developed PE and NT mothers who did not experience complications (adjusted
p≤0.05).
149
To further understand when these changes occur during gestation, we estimated the log fold-
change (logFC) for each gene by early, mid-, and late gestation as well as post-partum. We
observed that these gene changes occurred most strikingly in early and mid-gestation as indicated
by a clear bimodal distribution with two peaks centered around logFC of ±0.75 and broadly showed
no difference at post-partum (mean logFC = 0.02) (Fig 2A). We then quantified the relative
dispersion around the estimated logFC for each gene using an approximation for the coefficient of
variation (CV) or the ratio between an error bound, ∂, and the estimated logFC (Fig 2B). After
bootstrapping ∂, defined here as the error bound associated with the lower (or upper in the case of
negative logFC values) 95% confidence interval (CI), we found that gene changes were most stable
during early and mid-gestation where over 40% of genes had a CV < 1 as compared to 27% at late
gestation and 21% at post-partum.
161
We then asked whether a subset of gene changes approximately proportional in number to total
sample number (n = 27, 28, 31, 30) was sufficient to segregate PE (n = 13, 14, 19, 16) and NT (n
= 14, 14, 12, 14) samples across gestation. We performed hierarchical clustering on a subset of all
DEGs for each sampled time group based on two criteria designed to identify gene changes that
were stable (CV < 0.5) and striking (|logFC| ≥ 0.75). In total, 51, 38, 17, and 14 genes met these
criteria in early, mid-, late gestation, and post-partum, respectively, of which only 11 genes met
the specific cutoff criteria at 2 or more timepoints (File S1). This method separated PE and NT
samples across gestation and at post-partum with good specificity (93 [71–99], 56 [32–80], 75
[47–92], and 86% [62–97%]) and sensitivity (85 [59–97], 79 [53–94], 74 [52–89], and 81% [57–
94%]) (Fig 2C, values reported for early, mid-, and late gestation and post-partum, [95% CI]).
172
Noting that only 11 genes were shared across timepoint specific DEG subsets after applying hard
cutoffs, we then wondered whether changes associated with each subset persisted across
timepoints but at reduced levels. Further analysis indicated that genes identified at one timepoint
(i.e., early gestation) can moderately separate PE and NT samples from other timepoints (i.e., mid-
and late gestation and post-partum), and that typically such separation is most pronounced at a
timepoint closest to that in which the gene changes were identified (Fig S3). Finally, we validated
4 DEG changes in early and mid-gestation using RT-qPCR and validation dataset samples. For all
but 1 gene at 1 timepoint (PLAC8, mid-gestation), which had a CV close to 1 indicating reduced
confidence in the estimate, we found that the logFC estimated using this method were consistent
with those estimated in discovery using RNAseq, an orthogonal method (Fig S4).
183

Next, we sought to understand these changes' longitudinal dynamics over gestation using k-means clustering. We observed that the 556 identified DEGs could be well categorized into 3 distinct trends (Fig 2D, S5). Resembling a valley or V-shape, the first trend (Group 1) described the longitudinal behavior of 66 genes (12%), for which measured levels were significantly reduced in PE samples (-2x to -4x) across gestation with a minimum in mid-gestation. Peaking in early gestation (2x), the second trend (Group 2) described the behavior of 212 genes (38%) that had significantly elevated levels in PE samples across early and mid-gestation and to a lesser extent in late gestation (1.4x). Finally, the third trend (Group 3) described the behavior of 278 (50%) genes with consistently lower levels (-1.4x) across gestation. In all cases, gene changes were far less evident post-partum and trended toward no difference between PE and NT, which may reflect a placental contribution to DEG levels. Separately, we confirmed that these patterns were not spurious (i.e., an artifact of the k-means clustering algorithm) by permuting the data thereby scrambling any time-related structure while preserving its overall distribution. Following permutation, we observed no longitudinal patterns, which were instead replaced by 3 nearly flat, uninformative trends (Fig S6).

Finally, we asked what pathways these genes participated in. Grouping genes by longitudinal behavior, GO analysis revealed clear associations with PE pathogenesis and progression (Fig 2E) (See File S2 for full list). Broadly, genes with decreased levels across gestation in Groups 1 and 3 corresponded to the immune response, cellular apoptosis (i.e., TNFR1-mediated ceramide production), and cellular metabolism and catabolism (i.e., heterocycle metabolic process, regulation of catabolic process). In contrast, genes in Group 2 that had increased levels across gestation were involved in endothelial function (i.e., platelet activation, signaling, and aggregation), cellular activation (i.e., signaling by Rho GTPases), cellular invasion (i.e., lamellipodium organization), and wound healing (i.e., hemostasis).

Development of a machine learning classifier to predict future PE onset on or before 16 weeks of gestation

Having established that we can observe gene changes associated with the development of PE across gestation, we sought to build a robust classifier that can identify mothers at risk of PE at or before 16 weeks of gestation. After training, the final model performed well on the discovery dataset with a near perfect AUC (94%, [87–100%]), perfect specificity (100%, [91–100%]) and positive predictive value (PPV) (100%, [89–100%]), and high sensitivity (88%, [70–96%]) and negative predictive value (NPV) (89%, [74–97%]) (Fig 3A, Table 1).

We then tested this model on a completely independent cohort recently reported on by Del Vecchio and colleagues [31] who isolated and sequenced cfRNA from 25 samples collected between 12–17 weeks of gestation from mothers who experienced diverse complications (n = 8 NT, 8 with PE/gestational hypertension, 7 with gestational diabetes, 2 with chronic hypertension). Across this entire dataset, the final model once again performed well with high AUC (88%. [78–97%]), perfect sensitivity (100%, [74–100%]) and NPV (100%, [83–100%]), and good specificity (76%, [53–91%]) and PPV (67%, [39–88%]) (Fig 3A, Table 1).

Upon further inspection of the 4 erroneously classified samples (false positives), 1 and 2 were from mothers who had chronic hypertension or later developed gestational diabetes, respectively – known risk factors for PE [38–44]. To match our discovery cohort's control group, we then focused

230 on comparing samples from PE or gestational hypertension to samples from NT participants alone
231 and observed an AUC (94%, [79–100%]) identical to that measured in the discovery cohort, and
232 equally high values for sensitivity (100%, [74–100%]), specificity (88%, [55–99%]), PPV (89%,
233 [59–99%]), and NPV (100%, [71–100%]).
234
The final model also proved well-calibrated across both datasets with a calibration curve slope of
about 1 (1.27, 1.06) and intercept of close to 0 (-0.06, -0.05) (Values reported as Discovery, Del
Vecchio et al.). The probability of PE was also estimated as nearly 0% for most NT or otherwise
complicated pregnancy samples and as almost 100% for PE or gestational hypertension samples.
Far fewer samples were estimated to have a 50% probability of PE, the cutoff for classification
(Fig 3B).
241
We then wondered whether this model provided any predictive power for samples collected later
in gestation or at diagnosis between 17-38 weeks' gestation. To answer this, we measured model
performance across three datasets: the discovery cohort (samples collected ≥ 16 weeks of gestation
but not post-partum) and two independently collected cohorts [30]. For both independent cohorts
(iPEC, PEARL-PEC), Munchel and colleagues isolated and sequenced cfRNA from 97 NT (n =
73, 24) and PE (n = 40, 24) samples collected at time of PE diagnosis or a matched timepoint for
NT samples. As expected, we found a reduced, but still significant, signal to predict PE with
moderate AUC (79% [64–93%], 60% [50–69%], 62% [49–77%]), sensitivity (73 [48–90], 68 [52–
80], 62 [43–80%]), and specificity (85 [59–97], 52 [41–63], 62 [43–80%]) (Values reported
as discovery, iPEC, PEARL-PEC) (Table S2, Fig 3C). At these later gestational timepoints shortly
prior to or at diagnosis, the model remains moderately calibrated in discovery and poorly calibrated
in testing with a calibration curve slope of less than 1 (0.7, 0.07, 0.12) and intercept of close to 0
(0.06, 0.28, 0.43) (Values reported as discovery, iPEC, PEARL-PEC). Nonetheless, the model still
discriminated between PE and NT pregnancies with many samples still receiving probability
estimates at either extreme (0 or 100%) but an increased sample number with poor scores around
50% (Fig 3D) (All reported as value, [95% CI]).
258
Finally, we inspected the 11 genes (Table S3) used by the model to yield probability estimates.
We find that many of the trends (i.e., decreased or increased gene levels in PE) observed in the
discovery dataset are upheld in Del Vecchio and colleagues' dataset, although not to the level of
statistical significance after multiple hypothesis correction (adjusted p ≥ 0.40, one-sided Mann-
Whitney rank test) (Fig 3E). We also found that some models trained using a subset of the 11
initial genes can predict future PE onset with varying performance. Notably, performance
improved across all metrics (sensitivity, specificity, PPV, NPV, and AUC) as we increased the
number of genes included for model training with some subsets of sizes 4–10 achieving nearly
equivalent performance to the full model, which further emphasizes the importance of the gene
signature in aggregate as opposed to individually (Table S4, Fig S7).
269
Discussion
Noninvasive measurements of the cf-transcriptome present an opportunity to study human
development and disease from any organ at a molecular scale. Here, we show that cfRNA
measurements taken during pregnancy can clearly distinguish between PE and NT pregnancies
with the most striking differences occurring early on and broadly showed no difference at post-
partum, consistent with known PE biology, namely that the placenta drives the disease process

[32,33]. These findings are supported by orthogonal analyses including clustering and machine
learning. Specifically, we find that the most striking and stable changes as defined by high |logFC|
and low CV occur more frequently in early or mid-gestation as compared to later on and as broadly
supported by longitudinal dynamics analysis. Our observation that cfRNA changes are less stable
in late gestation may be consistent with what is known about fetal development over gestation,
specifically that fetal variability increases with gestation as supported by ultrasound data [45].
Importantly, small subsets of the DEGs identified here (n = 11–51) can also be used to separate
PE and NT pregnancies with the best sensitivity and specificity observed early in pregnancy as
confirmed by both hierarchical clustering and machine learning.

The genes we identify and their longitudinal dynamics are also consistent with what we know
about PE, namely that it likely develops very early in pregnancy with the resultant maternal
syndrome manifesting later [32]. Following GO analysis, we find that the DEGs identified here both
agree with prior evidence regarding PE's pathology and clinical presentation and provide new
hypotheses to explore. Specifically, GO terms that relate to cellular invasion and organ perfusion
(i.e., lamellipodium organization and hemostasis, Group 2), cellular apoptosis, catabolism and
response to stress (i.e., TNFR1-mediated ceramide production, regulation of catabolic process,
Groups 1 and 3), and endothelial dysfunction (i.e., platelet activation, signaling, and aggregation,
Group 2) closely reflect what is known about the stages of the pathogenesis of PE: abnormal
placentation as characterized by insufficient placental invasion of the uterine arteries and
subsequent reduced placental perfusion, inadequate nutrient exchange, and systemic endothelial
dysfunction [32].

Early in pregnancy during normal placentation, cytotrophoblasts invade the spiral arteries, which
then undergo a transformation to accommodate larger blood volumes for increased fetal and
placental nutrient requirements later in pregnancy, and peripheral villi regress via a mechanism
involving oxidative stress. PE is thought to be a uniquely human disease because of the large
nutritional exchange requirement imposed on the mother (3x higher than that for other mammals
in the third trimester) [32]. Later on, PE presents in the mother as systemic endothelial dysfunction,
where endothelial cells are closely implicated in platelet aggregation. Other terms like innate
immune system process, type I interferon production, and positive regulation of T cell
differentiation (Group 3) highlight the involvement of the innate and adaptive immune system,
which is both consistent with previous work on immune system dynamics during early gestation
in PE [46] and with known pregnancy biology about sustaining a successful pregnancy [47] and
establishing maternal tolerance, the lack of which has been previously associated with PE [48].

PE is also a broad and complex syndrome. Because the complication can present clinically across
more than 20 weeks with a diversity of symptoms, significant effort has been made to subclassify
the disease based on timing of onset. Used as a proxy for hypothesized pathogenesis, the timing
of PE onset subdivides the disease into 'placental' early-onset PE (occurring before 34 weeks of
gestation) and 'maternal' late-onset PE (occurring on or after 34 weeks) [32,34,49]. However, early-
and late-onset PE may represent a spectrum of disease severity that corresponds with timing of
onset and may lead to additional pregnancy complications, such as intrauterine growth restriction
(IUGR) [32,33,35,36]. Indeed, some evidence like transcriptional profiling of whole blood drawn at
diagnosis suggests a common gene signature for both subtypes [37]. Our findings further corroborate

that timing of onset may lie on a spectrum, and a common signature can identify both early- and late-onset PE of varied severity very early in gestation including as early as 5 weeks.

Finally, prediction of PE early in pregnancy has remained an unrealized objective for the field of obstetrics with important health consequences. Our results here provide encouraging evidence that it is possible both to predict PE risk before 16 weeks of gestation with high specificity and sensitivity, and to differentiate PE from other pregnancy-related complications such as gestational diabetes or underlying conditions such as chronic hypertension in a small, independent cohort. Of the 7 gestational diabetes samples included in the independent cohort of Del Vecchio et al., only 2 were misclassified as PE. We note that identifying other adverse outcomes that increase one's risk of PE may be an acceptable error mode whereas classifying an uncomplicated, NT pregnancy as PE is not and would result in unnecessary, added stress. In our analysis, we found that only 1 NT pregnancy was misclassified across 25 discovery and 8 test samples. Given the small sample size and limited ethnic and racial diversity in these cohorts, we emphasize that the performance metrics although consistent and striking must still be validated in a larger and more diverse follow-up study.

Notably, these predictions also relied on only 11 gene measurements – none of which overlapped with previously reported genes that are not altered until much closer to diagnosis (sFlt1 and PlGF) [25] or the cfRNA results in recent proof-of-concept work [30,31]. We also note that 11 genes can be easily measured using RT-qPCR, highlighting its clinical relevance and presenting an inexpensive alternative to RNAseq in future validation work. Given that both expense and efficacy are important factors in addressing barriers to care, an inexpensive test with striking efficacy may dramatically improve care and prevent missed or delayed diagnoses, which at the moment may account for as many as 3 in 5 maternal deaths related to pregnancy in the US [8].

Tests such as this one that identify who is at risk of PE early in pregnancy have long been acknowledged as an unrealized key objective in PE care [9]. They can also importantly be coupled with the administration of low-dose aspirin, which if started early has been shown to reduce risk of developing PE [10,28]. Although these results must be further confirmed in a blinded, larger validation study, the findings reported here demonstrate that an 11 gene cfRNA-based classifier can predict risk of PE with consistent, clinically relevant high sensitivity and specificity (88–100% for both metrics) across 2 independent datasets that were collected and processed by completely separate teams.

Taken together, we have shown that cfRNA measurement can form the basis for a robust liquid biopsy test that predicts PE very early in gestation, to date an unrealized key objective for obstetric care, and can be used to help characterize the pathogenesis of PE in real time.

Acknowledgements. We thank N. Aghaeepour and I. Maric from Stanford University for helpful
discussion and data analysis suggestions, the many researchers and clinicians affiliated with the
March of Dimes Prematurity Research Center at Stanford University for insightful feedback after
oral presentations, and the participants in this study for their invaluable contribution.

Funding. This work was supported by the Chan Zuckerberg Biohub and the March of Dimes
Foundation. The March of Dimes Foundation provided funding for sample collection and
processing. The Chan Zuckerberg Biohub provided funding for RNA sequencing and cloud
computing. M.N.M. is supported by the Stanford Bio-X Bowes Fellowship. V.D.W. is supported
by the H&H Evergreen Fund.

Author contributions. M.N.M., G.M.S., D.K.S., and S.R.Q. conceptualized and designed this
study. M.L.D., V.D.W., G.M.S., and D.K.S. designed the cohort study at Lucile Packard
Children's Hospital. R.J.W., A.A.C., and C.C.Q. collected and processed whole blood samples
and corresponding sample and participant metadata. M.N.M. developed experimental protocols
for cfRNA extraction and data generation and processed all samples from cfRNA extraction up to
and including RT-qPCR and library generation for RNA sequencing. R.V.S., M.T., and N.F.N.
developed and executed experimental protocols for RNA sequencing and computational protocols
for raw sequencing data transfer. M.N.M. conceptualized and developed computational analyses,
analyzed the data, and wrote the initial manuscript draft in collaboration with S.R.Q.. All authors
contributed to the writing and editing the manuscript.

Competing interests. The authors declare the following competing interests: M.N.M., G.M.S.,
D.K.S., and S.R.Q. are inventors on a patent application submitted by the Chan Zuckerberg Biohub
and Stanford University that covers noninvasive early prediction of preeclampsia. S.R.Q. is a
founder, consultant, and shareholder of Mirvie.

Materials & methods

Clinical study design
For this longitudinal, prospective study, we enrolled pregnant mothers (aged 18 years or older)
receiving routine antenatal care on or prior to 12 weeks of gestation at Lucile Packard Children's
Hospital at Stanford University, following study review and approval by the Institutional Review
Board at Stanford University (#21956). All signed informed consent prior to enrollment. Whole
blood samples for plasma isolation were then collected at three distinct timepoints during their
pregnancy course and once post-partum. Mothers were defined as having PE (cases, n = 38) based
upon current American College of Obstetrics and Gynecology (ACOG) guidelines (see below).
Our control (NT) cohort (n = 28) consisted of women who had uncomplicated term pregnancies
and either normal spontaneous vaginal or caesarean deliveries. For mothers who developed PE, all
antenatal samples included in this study were collected prior to clinical diagnosis.

Definition of preeclampsia
Preeclampsia was defined per the ACOG guidelines [27] based on two diagnostic criteria: 1) new-
onset hypertension developing on or after 20 weeks of gestation and 2) new-onset proteinuria or
in its absence, thrombocytopenia, impaired liver function, renal insufficiency, pulmonary edema,
or cerebral or visual disturbances.

405
New-onset hypertension was defined when the systolic and/or diastolic blood were at least 140 or
90 mmHg, respectively, on at least 2 separate occasions between 4 hours and 1 week apart.
Proteinuria was defined when either 300 mg protein was present within a 24-hour urine collection
or an individual urine sample contained a protein/creatinine ratio of 0.3 mg/dL, or if these were
not available, a random urine specimen had more than 1 mg protein as measured by dipstick.
Thrombocytopenia, impaired liver function, and renal insufficiency were defined as a platelet
count of > 10,000/μL, liver transaminases ≥ 2x of normal, and serum creatinine > 1.1 mg/dL,
respectively.
414
Symptoms were defined as severe per the ACOG guidelines. Specifically, PE is defined as severe
if any of the following symptoms were present and diagnosed as described above: new-onset
hypertension with systolic and/or diastolic blood pressure of at least 160 or 110 mmHg
respectively, thrombocytopenia, impaired liver function, renal insufficiency, pulmonary edema,
new-onset headache unresponsive to medication and unaccounted for otherwise, or visual
disturbances.
421
422 Finally, a pregnant mother was considered to have early-onset PE if onset occurred before 34
423 weeks of gestation and late onset thereafter.
424
Sample preparation
Plasma processing
Blood samples were collected in either EDTA-coated (Cat No 368661, Becton-Dickinson) or
Streck cfRNA BCT (Cat No 218976, Streck) tubes at early, mid, and late gestation, and post-
partum for each participant. Within 30 minutes, tubes were then centrifuged at 1600g for 30
minutes at room temperature. Plasma was transferred to 2-mL microfuge tubes and centrifuged at
13000g for another 10 minutes in a microfuge. One milliliter aliquots were then transferred to 2-
mL Sarsted screw cap microtubes (Cat No 50809242, Fisher Scientific) and stored at -80˚C until
analysis.
434
cfRNA isolation
In 96-sample batches, cfRNA from 1 mL plasma samples was extracted in a semi-automated
fashion using the Opentrons 1.0 system and Norgen Plasma/Serum Circulating and Exosomal
RNA Purification 96-Well Kit (Slurry Format) (Cat No 29500, Norgen). Samples were
subsequently treated with Baseline-ZERO DNAse (Cat No DB0715K, Lucigen) for 20 minutes at
37˚C. DNAse-treated cfRNA was then cleaned and concentrated into 12 μL using Zymo RNA
Clean and Concentrator-96 kit (Cat No R1080, Zymo).
442
443 Following cfRNA extraction from plasma samples, isolated RNA concentrations were estimated
444 for a randomly selected 11 samples per batch using Bioanalyzer RNA 6000 Pico Kit (Cat No 5067-
445 1513, Agilent) per manufacturer instructions.
446
Sequencing library preparation
cfRNA sequencing libraries were prepared with SMARTer Stranded Total RNAseq Kit v2 - Pico
Input Mammalian Components (Cat No 634419, Takara) from 4 μL of eluted cfRNA according to
the manufacturer's instructions. Samples were barcoded using SMARTer RNA Unique Dual Index

Kit – 96U Set A (Cat No 634452, Takara), and then pooled in an equimolar fashion and sequenced
on Illumina's NovaSeq platform (2x75 bp) to an average depth of 50 million reads per sample.
453

RT-qPCR assay
We performed RT-qPCR in two stages: reverse transcription and preamplification followed by
Taqman probe-based qPCR per manufacturer instructions. All primers and controls were
commercially designed and validated (Bio-Rad), and their unique assay IDs can be found in the
supplement (Table S5). Specifically, we prepared cDNA using random hexamers from an initial
volume of 4 µL cfRNA per sample (Bio-Rad Reliance Select cDNA Synthesis Kit, Cat No
12012801). Prior to reverse transcription (RT), we spiked in 1 µL RT control probe into each
sample to measure the latter step's efficiency. After RT, we combined 5 µL of prepared cDNA
with a primer pool, which was then preamplified for 12 cycles and subsequently diluted 1:5 (Tris
EDTA) (Bio-Rad SsoAdvanced PreAmp Supermix, Cat No 1725160). Finally, we performed each
qPCR assay in triplicate on the Bio-Rad CFX384 touch machine. Each replicate contained 1 µL
of pre-amplified and diluted cDNA sample, 0.5 µL of the corresponding primers, and super-mix
at the appropriate concentration (Bio-Rad SsoAdvanced Universal Probes Supermix, Cat No
1725285). Following qPCR, cycle threshold (C_t) values were extracted using CFX software.
468

Sequencing data analysis
Bioinformatic processing
For each sample, raw sequencing reads were trimmed using trimmomatic (v 0.36) and then mapped
to the human reference genome (hg38) with STAR (v 2.7.3a). Duplicate reads were then removed
by GATK's (v 4.1.1) MarkDuplicates tool. Finally, mapped reads were sorted and quantified using
htseq-count (v 0.11.1). Read statistics were estimated using FastQC (v 0.11.8).
475

476   Across samples, the bioinformatic pipeline was managed using snakemake (v 5.8.1). Read and tool
477   performance statistics were aggregated across samples and steps using MultiQC (v 1.7). Following
478   sample quality filtering, all gene counts were adjusted to log_2-transformed counts per million reads
479   (CPM) with trimmed mean of M values (TMM) normalization [50].
480

Sample quality filtering
For every sequenced sample, we estimated three quality parameters as previously described [51,52].
To estimate RNA degradation in each sample, we first counted the number of reads per exon and
then annotated each exon with its corresponding gene ID and exon number using htseq-count.
Using these annotations, we measured the frequency of genes for which all reads mapped
exclusively to the 3' most exon as compared to the total number of genes detected. RNA
degradation for a given sample can then be approximated as the fraction of genes where all reads
mapped to the 3' most exon. To estimate ribosomal read fraction, we compared the number of
reads that mapped to the ribosome (Region GL00220.1:105424-118780, hg38) relative to the total
number of reads (Samtools view). To estimate DNA contamination, we quantified the ratio of
reads that mapped to intronic as compared to exonic regions of the genome.
492

493   After measuring these three metrics across nearly 700 samples, we empirically estimated each
494   one's 95th percentile bound. We considered any given sample an outlier, low quality sample if its
495   value for at least one of these metrics was greater than or equal to the 95th percentile bound.
496

Once values for each metric was estimated across the entire dataset, we visualized: (1) whether
low-quality samples clustered separately using hierarchical clustering (average linkage, Euclidean
distance metric) and (2) whether sample quality drove variance in gene measurements using
principal component analysis (PCA). These analyses were performed in python (v 3.6) using
scikit-learn for PCA (v 0.23.2), scipy for hierarchical clustering (v 1.5.1), and nheatmap for
heatmap and clustering visualization (v 0.1.4).
503
Differential expression analysis
Differential expression analysis was performed in R using limma (v 3.38.3). To identify gene
changes associated with PE across gestation, we used a mixed-effects model and included
gestational age (continuous variable), case (binary variable, NT = 0 vs PE = 1), and the interaction
between the two in the design matrix. We chose to model gestational age as a continuous variable,
specifically a natural cubic spline with 4 degrees of freedom to account for the range across which
samples were collected (1–3 months per collection period). We also blocked for participant
identity (categorical variable), modeling it as a random effect to account for auto-correlation
between samples from the same person. Post-partum samples were excluded from differential
expression, instead serving as a hold-out dataset since they presented a clear break in gestational
time.
515
Per the limma-voom guide, to account for sample auto-correlation over time, we ran the function
voomWithQualityWeights twice. We first ran it without any blocking on participant identity, and
used this base estimation to approximate sample auto-correlation based on participant identity
using the function duplicateCorrelation. After estimating correlation, voomWithQualityWeights
was run again, this time blocking for participant identity and including the estimated auto-
correlation level. A linear model was then fit for each gene using lmFit and differential expression
statistics were approximated using Empirical Bayes (eBayes) methods. Finally, differentially
expressed genes were identified using the relevant design matrix coefficients and the function,
topTable, with Benjamini-Hochberg multiple hypothesis correction.
525
log(Fold change) and coefficient of variation (CV) estimation
We define $\log_2$-transformed fold-change (logFC) as the difference between the median gene level
(logCPM, see Bioinformatic processing section above) between PE and NT samples for a given
sample collection period (i.e., early, mid, and late gestation, or post-partum). In the case where a
given person had multiple samples included into a specific collection period, we only used the
values associated with the first collected sample to avoid artificially reducing within-group (PE or
NT) variance due to auto-correlation among samples from the same person.
533
We define the CV using an approximation. Specifically, we consider CV to be the ratio between
an error bound, ∂, and the estimated logFC. We defined the error bound, ∂, as the one-sided error
bound associated with the lower (or upper in the case of negative logFC values) 95% CI as
estimated by bootstrapping. This definition of ∂ as a one-sided bound that approaches 0 (equivalent
to no FC) allowed us explore how confident we could be in an estimated logFC. For instance, a
CV = 1 would indicate that at the boundary of proposed values, the logFC for a given gene becomes
effectively 0. Similarly, a CV > 1 would indicate even less confidence in a proposed average logFC
and indicate that at the boundary, the estimated logFC changes signs (i.e., a negative logFC
becomes a positive one or vice versa).

Hierarchical clustering analysis

For each sample collection period, hierarchical clustering was performed using differentially expressed genes with an $|logFC| \geq 0.75$ and CV < 0.5. For each gene that passed these thresholds, we calculated a z-score across all samples (at most 1 per subject, the earliest collected sample in a given group) in each sample collection period using the function StandardScaler in scikit-learn (v 0.23.2), Average linkage hierarchical clustering with a Euclidean distance metric was then performed for both rows (gene z-scores) and columns (samples in same collection group) for a given matrix in python using scipy (v 1.5.1). Clustering and corresponding heatmaps were visualized using nheatmap (v 0.1.4).

Longitudinal dynamics analysis

To group gene changes by longitudinal behavior, we performed k-means clustering on a matrix where each row was a differentially expressed gene and each column was the estimated logFC for a given sample collection period (556 genes x 4 timepoints). We measured the sum of squared distances for every 'k' between 1 and 16 (4^2) where 16 represents the maximum possible k (4 timepoints with 2 possibilities each, logFC > 0 or logFC < 0). We then identified the optimal k clusters using the well-established elbow method to identify the smallest 'k' that can best explain the data, visually described as the elbow (or knee) of a convex plot like that for the sum of squared distances vs k (Fig S5). To do so, we used the function KneeLocator as implemented in the package kneed (v 0.7.0). Having identified the optimal number of clusters, 'k', we labeled every differentially expressed gene with its assigned cluster and visualized average behavior (mean) and the 95% CI per cluster using Seaborn line plot (v 0.10.0).

To confirm that the identified patterns were not spurious (i.e., an artifact of the k-means clustering algorithm), we permuted the data columns (logFC per timepoint) for each gene thereby scrambling any time-related structure while preserving its overall distribution. We then visualized the result using Seaborn line plot as described above.

Gene ontology (GO) analysis

GO analysis was performed using the tool, GProfiler (v 1.0.0), for the following data sources, Gene ontology: biological processes (GO:BP) and Reactome (REAC). In identifying GO terms, electronic GO annotations (IEA) were included in the analysis. DEGs related to the ribosome were excluded from GO analysis given their extensive annotation that can lead to spurious term associations. To narrow this initial list (77 GO terms) to a smaller number for plotting purposes, the initial GO table was then pruned to only include parent terms (as filtered by the column, parents).

Logistic regression feature selection and training

To build a robust classifier that can identify mothers at risk of PE at or before 16 weeks of gestation, we first pre-selected features using the differential expression analysis (see section with same name above) as a starting point. Next, to correct for batch effect, where we define batch as a set of samples processed at the same time by a distinct group (e.g., Discovery cohort = batch, Del Vecchio and colleagues' cohort = batch), we subtracted the mean logCPM per gene from all cfRNA measurements in the batch (zero-centering). We note that all cohorts used in this work had balanced batch-group design and therefore met the requirements for zero-centering to work as

589   expected [53]. Model training then used the entire discovery dataset and consisted of two stages –
590   further feature pre-selection based on three metrics followed by the construction of a logistic
591   regression model with an elastic net penalty.
592
For feature pre-selection, we focused on three practical metrics measured across all samples
collected on or before 16 weeks of gestation: gene change size (|logFC|), gene change stability
(CV), and median gene expression (median CPM). Filtering on median gene expression helped
ensure that any genes selected could be robustly detected in smaller initial plasma volumes like
those that might be drawn in the clinic. All model hyperparameters and feature pre-selection
cutoffs were tuned using accuracy as the outcome metric and leave-one-out cross validation.
599
600   To understand the importance of each gene feature, we trained a separate logistic regression model
601   for every possible feature subset (2046 total combinations of 1-10 genes). No feature pre-selection
602   was performed for this sub-analysis. All model hyperparameters were tuned as previously
603   described. We defined a gene subset as weakly predictive if the model yielded an AUC > 50% on
604   the test sets (dataset of Del Vecchio et al.).
605
606   In all cases, performance metrics were assessed as described below (see next section).
607
Calibration analysis
We assessed model calibration using the calibration curve's slope and intercept as recommended
by Van Calster and colleagues [54] for small sample numbers (i.e., n < 200 for case group, n < 200
for control group). Specifically, we estimated the calibration curve using the function,
calibration_curve, from sklearn.calibration and 10 bins. We then estimated slope and intercept
using the function polyfit with 1 degree from numpy. As described by Van Calster and colleagues,
we considered a well-calibrated model to have a slope of approximately 1 and an intercept of
approximately 0. Curve slopes greater than 1 suggested moderate, underestimated risk scores
whereas slopes less than 1 suggested the opposite. Additionally, negative calibration curve
intercept values suggested underestimation whereas positive values suggested overestimation.
618
Performance metric analysis
Model performance was assessed using several statistics including sensitivity, specificity, PPV,
NPV, and ROC AUC. Given a 2x2 confusion matrix where rows 1and 2 represent true negatives
and positives and columns 1 and 2 represent negative and positive predictions respectively, we can
define the value in row 1, column 1 as true negatives (TN), row 1, column 2 as false positives (FP),
row 2, column 1 as false negatives (FN), and row 2, column 2 as true positives (TP). We can then
define the following proportions: (1) Sensitivity = TP / (TP + FN) (2) Specificity = TN / (TN +
FP) (3) PPV = TP / (TP + FP) (4) NPV = TN / (TN + FN). For each proportion, we calculated 95%
CIs using Jeffrey's interval [55] and the function, proportion_confint, from
statsmodels.stats.proportion. We also approximated AUC and its corresponding 95% CI using the
scikit-learn function, roc_auc_score, and bootstrapping respectively.
630
RT-qPCR data analysis
Sample quality filtering
RT-qPCR and sample quality were assessed using two controls. First, we confirmed the absence
of genomic DNA contamination using a commercially available control (Table S5). Any sample

where genomic DNA was detected as defined by the manufacturer would have been excluded from
further analysis; however, in this work, no sample contained DNA contamination at a detectable
level. Next, we measured reverse-transcription efficiency (RT) using a control probe spiked in at
a known concentration prior to RT and subsequently measuring the probe's C_t following
preamplification (no primers included for RT in preamplification) and qPCR as detailed above
(see RT-qPCR assay). For inclusion in any further analysis, we required that the RT probe (at
levels below the corresponding non-template control) be detected in a given sample well.
642

Fold-change estimation
We estimated fold-change from RT-qPCR data using the $\Delta\Delta C_t$ method. Specifically, for every
gene of interest (G_i), we first estimated $\Delta C_t = C_t(G_i) - C_t(RT\ control)$ to account for different
reverse-transcription efficiencies across samples. For more details about the RT control, refer to
the sections titled "Sample quality filtering" and "RT-qPCR assay". Having defined ΔC_t for every
gene measured in each sample, we can then define $\Delta\Delta C_t$ for a given gene as the difference between
the median ΔC_t in the PE group and in the NT group. Fold-change can then be defined as $2^{-\Delta\Delta C_t}$.
650

651   **Statistical analysis**
652   All p-values reported herein were calculated using the non-parametric Mann-Whitney rank test
653   unless otherwise stated. One-sided tests were performed where required based on the hypothesis
654   tested.
655

656   **Code/data availability**
657   All computational analyses were performed using Python 3.6 or R 3.5, and will be available on
658   Github. Raw and processed sequencing and RT-qPCR data will be deposited with the SRA and
659   GEO respectively.
660

Figure 1. Sample, maternal, and pregnancy characteristics with the exception of gestational age at delivery are matched across NT and PE groups. Panels illustrate matched sample collection time (weeks) in (**A**), matched maternal characteristics (Left to right: BMI, age, and previous pregnancies) in (**B**), matched gestational age at PE onset regardless of PE symptom severity in (**C**), and gestational age at delivery in (**D**). For (**A**), schematic depicts blood sampling across gestation and plasma isolation. X-axis represents gestational age during pregnancy and time post-delivery (weeks) thereafter (ns = not significant, ** = 10^{-5}).

Figure 2. Across gestation and prior to diagnosis, changes in the cfRNA transcriptome segregate PE and NT samples and agree with known PE biology. (**A**) Distribution of log(Fold change) with dashed lines at log(Fold change) = ± 1 and (**B**) CVs with dashed line at CV = 1 for all differentially expressed genes between PE and NT samples across gestation. In (**B**), 2, 9, 5, and 10 genes with CV > 10 across early, mid-, late gestation and post-partum respectively are omitted. (**C**) Across gestation, in each sample collection period, a subset of differentially expressed genes can separate PE and NT samples despite differences in symptom severity, PE onset subtype, and gestational age (GA) at delivery. (**D**) Across gestation, differentially expressed genes can be described by 3 longitudinal trends as revealed by k-means clustering. (**E**) The genes in each longitudinal trend group reflect known PE biology as highlighted across two databases (GO biological processes and the reactome). Some PE associated terms are emphasized in bold, colored text that corresponds to group color. Heatmap only includes parent terms (see File S2 for full list).

Figure 3. A subset of cfRNA changes can predict risk of PE early in gestation (**A**, **C**) Classifier
performance as quantified by a receiver operating characteristic curve for samples collected in
early gestation between 5–16 weeks in (**A**) and samples collected later in gestation between 17–
38 weeks in (**C**). For each dataset, including 3 independent previously published datasets, legend
states the AUC and the corresponding 95% CI in square brackets. (**B**, **D**) Estimated probability of
PE as outputted by logistic regression for both PE and NT samples in each dataset shows that the
model is well-calibrated and fairly confident (probability(PE) = 0 or 1) across most predictions.
Dashed line at 0.5 indicates classifier cutoff where probability(PE) > 0.5 constitutes a sample
predicted as PE. (**E**) Prediction of PE incorporates cfRNA levels for 11 genes for which centered
$\log_2$(Fold change) trends hold across discovery and independent validation (Del Vecchio (2020))
datasets.

Table 1. PE prediction performance metrics for samples collected early in gestation (between
5–16 weeks). Control and case sample numbers are reported as the total sample number and in
parentheses, the number of samples misclassified. Case column also include the sample number
split between PE and gestational hypertension (GH) cases in square brackets. All other statistics
including sensitivity specificity, PPV, NPV, and AUC are reported as the estimated percentage
followed by the 95% CI in square brackets. In Del Vecchio[1], the control group is defined as
samples from any pregnant mother who did not develop PE or GH including those with other
underlying or pregnancy-related complications like chronic hypertension and gestational diabetes
respectively. In Del Vecchio[2], the control group is defined as samples strictly from NT pregnant
mothers who did not experience complications.
706

	Control (n)	Case (n)	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	AUC (%)
Discovery	25 (0)	24 (3) [All PE]	88 [70-96]	100 [91-100]	100 [89-100]	89 [74-97]	94 [87-100]
Del Vecchio[1] (2020)	17 (4)	8 (0) [5 PE, 3 GH]	100 [74-100]	76 [53-91]	67 [39-88]	100 [83-100]	88 [78-97]
Del Vecchio[2] (2020)	8 (1)	8 (0) [5 PE, 3 GH]	100 [74-100]	88 [55-99]	89 [59-99]	100 [71-100]	94 [79-100]

708 **Supplementary text**
709
Supplementary note 1: Establishing quality metrics to identify sample outliers
Because cfRNA measurements can be noisy [30,56], we have previously developed and reported on
three quality metrics that can flag sequenced cfRNA samples with poor quality [51,52]. Specifically,
these metrics aim to quantify unusually high levels of RNA degradation, DNA contamination,
and/or ribosomal RNA by comparing a given sample's value for any of these metrics with what
we expect empirically. We defined reasonable expected values for each metric based on the 95th
percentile for ~700 previously sequenced samples across 3 cohorts.
717
We found that samples with outlier values for at least one of these three metrics both clustered
separately (Fig S1) and served as leverage points in principal component analysis (PCA) (Fig
S2A). To avoid introducing unwanted bias, we removed these low-quality samples from any
further analysis. After removing outlier samples, we reran PCA and noticed that two samples
continued to serve as leverage points (Fig S2B). We suspected that this may be due to genes that
were poorly detected and consequently performed further filtering to identify well-detected genes
across the entire cohort. Specifically, we used a basic cutoff that required a given gene be detected
at a level of at least 0.5 counts per million reads (CPM) in at least 75% of samples after removing
outlier samples. Following this step, we retain 7,041 genes for analysis. Upon inspection, we find
that visualization using PCA is no longer driven by leverage points (Fig S2C).

Fig S1. Samples with outlier values for at least one of QC metric cluster separately from most
non-outlier samples.

Fig S2. Sample outliers and poorly detected genes drive principal component analysis (PCA)
and serve as leverage points. Visualization of the top two principal components when performed
using all samples and all genes (**A**) or only samples that pass QC metrics (**B**) reveals that certain
samples can act as leverage points. Once sample outliers and lowly detected genes are removed
from the cfRNA gene matrix (**C**), the top two principal components reflect natural variance in the
data and are no longer driven by a few leverage points.

Fig S3. Across gestation and prior to diagnosis, changes in the cfRNA transcriptome identified at one timepoint can moderately segregate PE and NT samples at other timepoints. Differentially expressed genes (DEGs) with |logFC| ≥ 0.75 and CV < 0.5 were identified at each timepoint across gestation. Each row visualizes how well a specific DEG subset from a given sample collection period can separate PE and NT samples in all other collection periods (columns). The number of genes identified per sample collection period is highlighted along the main diagonal.

Fig S4. Log(Fold change) as estimated by RNAseq and RT-qPCR across two cohorts (discovery and validation) broadly agree with the exception of PLAC8 at mid-gestation.

Fig S5. Longitudinal dynamics across gestation can be best described in 3 clusters. The
optimal k clusters (dashed line) or elbow of this convex plot comparing a performance metric, the
sum of squared distances, and values of k occurs at k = 3.

Fig S6. K-means clustering reveals meaningful longitudinal patterns. Following permutation
of the data matrix prior to k-means clustering, longitudinal changes over gestation are replaced by
3 flat lines.

Fig S7. Logistic regression models trained on subsets of 1–10 genes of the initial 11 genes can moderately predict future PE onset with improving performance as subset size increases and as characterized by sensitivity (**A**), specificity (**B**), PPV (**C**), NPV (**D**), and AUC (**E**). In Del Vecchio[1], the control group is defined as samples from any pregnant mother who did not develop PE or gestational hypertension including those with other underlying or pregnancy-related complications like chronic hypertension and gestational diabetes respectively. In Del Vecchio[2], the control group is defined as samples strictly from NT pregnant mothers who did not experience complications.

767 **Table S1. Participant, pregnancy, and PE characteristics across both discovery and**
768 **validation datasets.** Maternal age and BMI, gestational age (GA) at delivery, fetal weight, and
769 GA at PE onset are reported mean ± standard deviation. All other values are reported as
770 percentages. Small for GA (SGA) was defined as an infant with a birthweight below the 10th centile
771 for their GA at delivery.
772

Maternal pre-pregnancy characteristics

		Age (years)	BMI (kg/m^2)	Nulliparous (%)
Discovery	NT	32 ± 5	23 ± 3	44
	PE	31 ± 6	30 ± 8	38
Validation	NT	32 ± 3	25 ± 6	12
	PE	32 ± 4	26 ± 4	29

Maternal ethnicity/race

		Ethnicity	Race			
		Hispanic (%)	White (%)	Black (%)	Asian (%)	Unknown (%)
Discovery	NT	0	100	0	0	0
	PE	42	50	4	25	21
Validation	NT	38	100	0	0	0
	PE	57	86	0	14	0

Pregnancy characteristics

		GA at delivery (weeks)	Mode of delivery (% vaginal)	Multi-gestation (%)	Preterm delivery (%)	Fetal sex (% male)	Fetal weight (kg)	SGA (%)
Discovery	NT	40 ± 1	61	0	0	56	3.5 ± 0.4	0
	PE	36 ± 3	46	12	38	54	2.8 ± 0.7	4
Validation	NT	39 ± 1	62	0	0	25	3.6 ± 0.6	0
	PE	38 ± 1	57	0	14	57	3.4 ± 0.3	0

PE characteristics

		GA at onset (weeks)	Onset type (% early)	Symptom severity (% severe)	History of PE (%)
Discovery	PE	36 ± 4	25	54	17
Validation	PE	38 ± 2	0	43	14

774 **Table S2. PE prediction performance metrics for samples collected late in gestation or at PE**
775 **diagnosis (between 17–38 weeks).** Control and PE sample numbers are reported as the total
776 sample number and in parentheses, the number of samples misclassified. All other statistics
777 including sensitivity specificity, PPV, NPV, and AUC are reported as the estimated percentage
778 followed by the 95% CI in square brackets.

	NT (n)	PE (n)	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	AUC (%)
Discovery	13 (2)	15 (4)	73 [48-90]	85 [59-97]	85 [59-97]	73 [48-90]	79 [64-93]
Munchel (2020) iPEC	73 (35)	40 (13)	68 [52-80]	52 [41-63]	44 [32-56]	75 [61-85]	60 [50-69]
Munchel (2020) PEARL-PEC	24 (9)	24 (9)	62 [43-80]	62 [43-80]	62 [43-80]	62 [43-80]	62 [49-77]

781 **Table S3. PE prediction relies on the cfRNA levels of 11 genes.** For every gene, symbol,
782 ENSEMBL ID, full name, odds ratio (OR) based on the logistic regression coefficient, and a subset
783 of GO biological processes and molecular functions are reported from left to right.
784

Gene	ENSEMBL	Name	OR	Biological Process [GO]	Molecular Function [GO]
GSPT1	ENSG0000 0103342	G1 to S phase transition 1	1.69	regulation of translational termination, protein methylation, G1/S transition of mitotic cell cycle	GTPase activity, RNA binding, GTP binding, translation release factor activity, protein binding
BNIP3L	ENSG0000 0104765	BCL2 interacting protein 3 like	0	regulation of protein targeting to mitochondrion, defense response to virus, regulation of apoptotic process	lamin binding, protein homodimerization activity, identical protein binding, protein binding
MARCH2	ENSG0000 0099785	membrane associated ring-CH-type finger 2	0.02	protein ubiquitination, endocytosis	protein binding, ubiquitin protein ligase activity
IGF2	ENSG0000 0167244	insulin like growth factor 2	0.12	in utero embryonic development, platelet degranulation, regulation of gene expression by genetic imprinting	growth factor activity, integrin binding, insulin receptor binding, protein serine/threonine kinase activator activity
HEMGN	ENSG0000 0136929	hemogen	15.83	multicellular organism development, regulation of osteoblast differentiation, cell differentiation	protein binding
OAZ1	ENSG0000 0104904	ornithine decarboxy lase antizyme 1	51.6	positive regulation of intracellular protein transport, negative regulation of polyamine transmembrane transport	ornithine decarboxylase inhibitor activity, protein binding
CSF3R	ENSG0000 0119535	colony stimulatin g factor 3 receptor	0.19	regulation of myeloid cell differentiation, cytokine-mediated signaling pathway, cell	signaling receptor activity, cytokine receptor activity

				adhesion, defense response	
RPS15	ENSG0000 0115268	ribosomal protein S15	0.76	osteoblast differentiation, translation, rRNA processing	RNA binding, structural constituent of ribosome, protein binding
AKNA	ENSG0000 0106948	AT-hook transcripti on factor	0.08	neuroblast division in subventricular zone, regulation of inflammatory response, epithelial to mesenchymal transition	DNA binding, protein binding
SNCA	ENSG0000 0145335	synuclein alpha	2.09	calcium ion homeostasis, synaptic vesicle exocytosis, receptor internalization, regulation of norepinephrine uptake	actin binding, tau protein binding, SNARE binding, phosphoprotein binding, protein kinase inhibitor activity
FECH	ENSG0000 0066926	ferrochelat ase	1.98	response to drug, heme biosynthetic process	ferrochelatase activity, 2 iron

Table S4. Logistic regression models trained on some subsets of 4–10 genes of the initial 11 genes can predict future PE onset with nearly equivalent performance metrics. The associated performance metrics for each data split and some high-performing gene subsets is reported including sensitivity (Sens), specificity (Spec), PPV, NPV, and AUC, which are reported as the estimated percentage. In Del Vecchio[1], the control group is defined as samples from any pregnant mother who did not develop PE or gestational hypertension including those with other underlying or pregnancy-related complications like chronic hypertension and gestational diabetes respectively. In Del Vecchio[2], the control group is defined as samples strictly from NT pregnant mothers who did not experience complications.

Subset	Size	Del Vecchio et al (1)					Del Vecchio et al (2)				
		PPV	NPV	Sens	Spec	AUC	PPV	NPV	Sens	Spec	AUC
MARCH2, OAZ1, CSF3R, SNCA	4	64	93	88	76	82	88	88	88	88	88
GSPT1, MARCH2, OAZ1, CSF3R, SNCA	5	70	93	88	82	85	88	88	88	88	88
MARCH2, OAZ1, CSF3R, RPS15, AKNA, SNCA	6	70	93	88	82	85	88	88	88	88	88
MARCH2, HEMGN, OAZ1, CSF3R, RPS15, SNCA, FECH	7	70	93	88	82	85	88	88	88	88	88
GSPT1, MARCH2, HEMGN, OAZ1, CSF3R, RPS15, SNCA, FECH	8	70	93	88	82	85	88	88	88	88	88
BNIP3L, MARCH2, IGF2, HEMGN, OAZ1, CSF3R, RPS15, AKNA, FECH	9	67	100	100	76	88	89	100	100	88	94
BNIP3L, MARCH2, IGF2, HEMGN, OAZ1, CSF3R, RPS15, AKNA, SNCA, FECH	10	67	100	100	76	88	89	100	100	88	94

798   **Table S5. RT-qPCR Taqman probe details**. Unique AssayID corresponds to Biorad assay
799   identification codes.

	Fluorophore	Unique AssayID
FECH	FAM	qHsaCEP0049507
HEMGN	FAM	qHsaCEP0051994
PLAC8	FAM	qHsaCEP0052516
RPS16	FAM	qHsaCEP0050314
DNA contamination control	FAM	qHsaCtlP0001004
RT control	FAM	qHsaCtlP0001001

801   **File S1. Table of 108 differentially expressed genes included in Fig 2C heatmaps.** For every
802   gene, the symbol, ENSEMBL ID, sample collection groups for which the gene passed cutoff
803   thresholds, full name, ENSEMBL gene type, and a subset of GO biological processes and
804   molecular functions are reported.

806   **File S2. Table of all significant GO terms.**

Bibliography

1. Centers for Disease Control and Prevention (CDC). Healthier mothers and babies. *MMWR Morb. Mortal. Wkly. Rep.* **48,** 849–858 (1999).

2. Basso, O. *et al.* Trends in fetal and infant survival following preeclampsia. *JAMA* **296,** 1357–1362 (2006).

3. Behrman, R. E., Butler, A. S. & Institute of Medicine (US) Committee on Understanding Premature Birth and Assuring Healthy Outcomes. Societal Costs of Preterm Birth. (2007).

4. Blencowe, H. *et al.* Born too soon: the global epidemiology of 15 million preterm births. *Reprod Health* **10 Suppl 1,** S2 (2013).

5. Stevens, W. *et al.* Short-term costs of preeclampsia to the United States health care system. *Am. J. Obstet. Gynecol.* **217,** 237–248.e16 (2017).

6. Beam, A. L. *et al.* Estimates of healthcare spending for preterm and low-birthweight infants in a commercially insured population: 2008-2016. *J. Perinatol.* **40,** 1091–1099 (2020).

7. Say, L. *et al.* Global causes of maternal death: a WHO systematic analysis. *Lancet Glob. Health* **2,** e323-33 (2014).

8. Petersen, E. E. *et al.* Vital Signs: Pregnancy-Related Deaths, United States, 2011-2015, and Strategies for Prevention, 13 States, 2013-2017. *MMWR Morb. Mortal. Wkly. Rep.* **68,** 423–429 (2019).

9. McCarthy, F. P., Ryan, R. M. & Chappell, L. C. Prospective biomarkers in preterm preeclampsia: A review. *Pregnancy hypertension* **14,** 72–78 (2018).

10. Roberge, S. *et al.* The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. *Am. J. Obstet. Gynecol.* **216,** 110–120.e6 (2017).

11. Duley, L. The global impact of pre-eclampsia and eclampsia. *Semin Perinatol* **33,** 130–137 (2009).

12. Hutcheon, J. A., Lisonkova, S. & Joseph, K. S. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. *Best Pract Res Clin Obstet Gynaecol* **25,** 391–403 (2011).

13. Abalos, E., Cuesta, C., Grosso, A. L., Chou, D. & Say, L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. *Eur. J. Obstet. Gynecol. Reprod. Biol.* **170,** 1–7 (2013).

14. Zhang, J., Meikle, S. & Trumble, A. Severe maternal morbidity associated with hypertensive disorders in pregnancy in the United States. *Hypertens Pregnancy* **22,** 203–212 (2003).

15. Steegers, E. A. P., von Dadelszen, P., Duvekot, J. J. & Pijnenborg, R. Pre-eclampsia. *Lancet* **376,** 631–644 (2010).

16. Li, X. *et al.* Hypertensive disorders of pregnancy and risks of adverse pregnancy outcomes: a retrospective cohort study of 2368 patients. *J Hum Hypertens* (2020). doi:10.1038/s41371-020-0312-x

17. Hansen, A. R., Barnés, C. M., Folkman, J. & McElrath, T. F. Maternal preeclampsia predicts the development of bronchopulmonary dysplasia. *J. Pediatr.* **156,** 532–536 (2010).

18. Wang, A. *et al.* Circulating anti-angiogenic factors during hypertensive pregnancy and increased risk of respiratory distress syndrome in preterm neonates. *J. Matern. Fetal Neonatal Med.* **25,** 1447–1452 (2012).

19. Bellamy, L., Casas, J.-P., Hingorani, A. D. & Williams, D. J. Pre-eclampsia and risk of

cardiovascular disease and cancer in later life: systematic review and meta-analysis. *BMJ*
335, 974 (2007).

20. Ahmed, R., Dunford, J., Mehran, R., Robson, S. & Kunadian, V. Pre-eclampsia and future
cardiovascular risk among women: a review. *J. Am. Coll. Cardiol.* **63,** 1815–1822 (2014).

21. Vikse, B. E., Irgens, L. M., Leivestad, T., Skjaerven, R. & Iversen, B. M. Preeclampsia and
the risk of end-stage renal disease. *N. Engl. J. Med.* **359,** 800–809 (2008).

22. McDonald, S. D., Han, Z., Walsh, M. W., Gerstein, H. C. & Devereaux, P. J. Kidney disease
after preeclampsia: a systematic review and meta-analysis. *Am. J. Kidney Dis.* **55,** 1026–
1039 (2010).

23. Hypertension in pregnancy. Report of the American College of Obstetricians and
Gynecologists' Task Force on Hypertension in Pregnancy. *Obstet. Gynecol.* **122,** 1122–1131
(2013).

24. Goel, A. *et al.* Epidemiology and mechanisms of de novo and persistent hypertension in the
postpartum period. *Circulation* **132,** 1726–1733 (2015).

25. Zeisler, H. *et al.* Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected
Preeclampsia. *N. Engl. J. Med.* **374,** 13–22 (2016).

26. Sovio, U. *et al.* Prediction of Preeclampsia Using the Soluble fms-Like Tyrosine Kinase 1 to
Placental Growth Factor Ratio: A Prospective Cohort Study of Unselected Nulliparous
Women. *Hypertension* **69,** 731–738 (2017).

27. Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222. *Obstet.*
Gynecol. **135,** e237–e260 (2020).

28. Roberge, S. *et al.* Early administration of low-dose aspirin for the prevention of preterm and
term preeclampsia: a systematic review and meta-analysis. *Fetal Diagn Ther* **31,** 141–146
(2012).

29. Whitehead, C. L., Walker, S. P. & Tong, S. Measuring circulating placental RNAs to non-
invasively assess the placental transcriptome and to predict pregnancy complications.
Prenat. Diagn. **36,** 997–1008 (2016).

30. Munchel, S. *et al.* Circulating transcripts in maternal blood reflect a molecular signature of
early-onset preeclampsia. *Sci. Transl. Med.* **12,** (2020).

31. Del Vecchio, G. *et al.* Cell-free DNA Methylation and Transcriptomic Signature Prediction
of Pregnancies with Adverse Outcomes. *Epigenetics* 1–20 (2020).
doi:10.1080/15592294.2020.1816774

32. Phipps, E. A., Thadhani, R., Benzing, T. & Karumanchi, S. A. Pre-eclampsia: pathogenesis,
novel diagnostics and therapies. *Nat. Rev. Nephrol.* **15,** 275–289 (2019).

33. Burton, G. J., Redman, C. W., Roberts, J. M. & Moffett, A. Pre-eclampsia: pathophysiology
and clinical implications. *BMJ* **366,** l2381 (2019).

34. von Dadelszen, P., Magee, L. A. & Roberts, J. M. Subclassification of preeclampsia.
Hypertens Pregnancy **22,** 143–148 (2003).

35. Huppertz, B. Placental origins of preeclampsia: challenging the current hypothesis.
Hypertension **51,** 970–975 (2008).

36. Raymond, D. & Peterson, E. A critical review of early-onset and late-onset preeclampsia.
Obstet Gynecol Surv **66,** 497–506 (2011).

37. Chaiworapongsa, T. *et al.* Differences and similarities in the transcriptional profile of
peripheral whole blood in early and late-onset preeclampsia: insights into the molecular
basis of the phenotype of preeclampsiaa. *J Perinat Med* **41,** 485–504 (2013).

38. Ostlund, I., Haglund, B. & Hanson, U. Gestational diabetes and preeclampsia. *Eur. J.*

Obstet. Gynecol. Reprod. Biol. **113,** 12–16 (2004).

39. Schneider, S., Freerksen, N., Röhrig, S., Hoeft, B. & Maul, H. Gestational diabetes and
preeclampsia--similar risk factor profiles? *Early Hum. Dev.* **88,** 179–184 (2012).

40. Nerenberg, K. A. *et al.* Risks of gestational diabetes and preeclampsia over the last decade
in a cohort of Alberta women. *J Obstet Gynaecol Can* **35,** 986–994 (2013).

41. Weissgerber, T. L. & Mudd, L. M. Preeclampsia and diabetes. *Curr Diab Rep* **15,** 9 (2015).

42. Rey, E. & Couturier, A. The prognosis of pregnancy in women with chronic hypertension.
Am. J. Obstet. Gynecol. **171,** 410–416 (1994).

43. McCowan, L. M., Buist, R. G., North, R. A. & Gamble, G. Perinatal morbidity in chronic
hypertension. *Br J Obstet Gynaecol* **103,** 123–129 (1996).

44. Sibai, B. M. *et al.* The impact of prior preeclampsia on the risk of superimposed
preeclampsia and other adverse pregnancy outcomes in patients with chronic hypertension.
Am. J. Obstet. Gynecol. **204,** 345.e1-6 (2011).

45. Verburg, B. O. *et al.* New charts for ultrasound dating of pregnancy and assessment of fetal
growth: longitudinal data from a population-based cohort study. *Ultrasound Obstet.*
Gynecol. **31,** 388–396 (2008).

46. Han, X. *et al.* Differential dynamics of the maternal immune system in healthy pregnancy
and preeclampsia. *Front. Immunol.* **10,** 1305 (2019).

47. Ander, S. E., Diamond, M. S. & Coyne, C. B. Immune responses at the maternal-fetal
interface. *Sci. Immunol.* **4,** (2019).

48. Szarka, A., Rigó, J., Lázár, L., Beko, G. & Molvarec, A. Circulating cytokines, chemokines
and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex
suspension array. *BMC Immunol.* **11,** 59 (2010).

49. Lisonkova, S. & Joseph, K. S. Incidence of preeclampsia: risk factors and outcomes
associated with early- versus late-onset disease. *Am. J. Obstet. Gynecol.* **209,** 544.e1-
544.e12 (2013).

50. Robinson, M. D. & Oshlack, A. A scaling normalization method for differential expression
analysis of RNA-seq data. *Genome Biol.* **11,** R25 (2010).

51. Pan, W. Development of diagnostic methods using cell-free nucleic acids. (Stanford
University, 2016).

52. Moufarrej, M. N., Wong, R. J., Shaw, G. M., Stevenson, D. K. & Quake, S. R. Investigating
Pregnancy and Its Complications Using Circulating Cell-Free RNA in Women's Blood
During Gestation. *Front. Pediatr.* **8,** 605219 (2020).

53. Goh, W. W. B., Wang, W. & Wong, L. Why batch effects matter in omics data, and how to
avoid them. *Trends Biotechnol.* **35,** 498–507 (2017).

54. Van Calster, B. *et al.* Calibration: the Achilles heel of predictive analytics. *BMC Med.* **17,**
230 (2019).

55. Brown, L. D., Cai, T. T. & DasGupta, A. Interval Estimation for a Binomial Proportion. *Stat*
Sci **16,** 101–133 (2001).

56. Ibarra, A. *et al.* Non-invasive characterization of human bone marrow stimulation and
reconstitution by cell-free messenger RNA sequencing. *Nat. Commun.* **11,** 400 (2020).